Histopathological and Immunological Effects of Nebivolol 5% Topical Cream in Mice Model of Imiquimod-Induced Psoriasis
DOI:
https://doi.org/10.54133/ajms.v6i1.527الكلمات المفتاحية:
IL-10، IL-17، Imiquimod، Nebivolol، Psoriasis، TNF-α، VEGFالملخص
Background: Psoriasis is a chronic inflammatory skin condition that affects multiple systems. Topical therapy is one of the most important modalities in the treatment of this disease, and efforts are directed toward developing more effective topical therapies. Objective: To investigate the possible anti-psoriatic effect of Nebivolol 5% topical cream in mice based on observational, histopathological, and biochemical outcomes. Methods: Forty-five male Swiss Albino mice were divided into five groups; each group contained nine mice with shaved dorsal skin. Group I remained as the control group while the rest of the groups were induced psoriasis by Imiquimod (IMQ) for six consecutive days and underwent different interventions for each group for eight consecutive days, including administering Nebivolol 5% topical cream. The clinical, pathological and laboratory effects were then measured. Results: Topical nebivolol significantly reduced the inflammatory signs of the psoriatic lesions, and these findings were supported by the histopathological examination. Topical Nebivolol also significantly decreased IL-17 levels, as well as Tumor Necrosis Factor-alpha (TNF-α) levels and Vascular Endothelial Growth Factor (VEGF) levels, in comparison with the non-treated Imiquimod-induced psoriatic mice group. Conclusions: Nebivolol has a comparable anti-psoriatic effect to the effect of clobetasol due to its anti-inflammatory and antioxidant effects. It could be a promising future treatment for psoriasis as an alternative to steroids.
التنزيلات
المراجع
Mahmood DA, Sarhat ER, Sulaiman YA and Abass KS. Relationship between Paraoxonase and Malondialdehyde as a marker of oxidative stress in patients with psoriasis. Revista Latinoamericana de Hipertension. 2022;17(6). doi: 10.5281/zenodo.7406413.
Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P and Santos-Silva A. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol. 2012;51:389-395. doi: 10.1111/j.1365-4632.2011.05154.x. DOI: https://doi.org/10.1111/j.1365-4632.2011.05154.x
Chamian F and Krueger JG. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol. 2004;16:331-337. doi: 10.1097/01.bor.0000129715.35024.50. DOI: https://doi.org/10.1097/01.bor.0000129715.35024.50
van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182(9):5836-5845. doi: 10.4049/jimmunol.0802999. DOI: https://doi.org/10.4049/jimmunol.0802999
Pradhan M, Alexander A, Singh MR, Singh D, Saraf S, Saraf S, et al. Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother. 2018;107:447-463. doi: 10.1016/j.biopha.2018.07.156. DOI: https://doi.org/10.1016/j.biopha.2018.07.156
Ojji D, Ale BM, Shedul L, Umuerri E, Ejim E, Alikor C, et al. The effect of nebivolol on office blood pressure of blacks residing in Sub-Saharan Africa (A Pilot Study). Front Cardiovasc Med. 2021;7:613917. doi: 10.3389/fcvm.2020.613917. DOI: https://doi.org/10.3389/fcvm.2020.613917
Wehland M, Grosse J, Simonsen U, Infanger M, Bauer J and Grimm D. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease. Curr Vasc Pharmacol. 2012;10:378-390. doi: 10.2174/157016112799959323. DOI: https://doi.org/10.2174/157016112799959323
Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. J Cardiovasc Pharmacol. 2006;48:862-869. doi: 10.1097/01.fjc.0000238593.67191.e2. DOI: https://doi.org/10.1097/01.fjc.0000238593.67191.e2
Aly Labib D, Shaker O and Elfarouk L. Protective effects of nebivolol on acetic acid-induced ulcerative colitis in rats. Kasr Al Ainy Med J. 2016;22:99-108. doi: 10.4103/1687-4625.195889. DOI: https://doi.org/10.4103/1687-4625.195889
Fredriksson T, Pettersson U. Severe psoriasis – Oral therapy with a new retinoid. Dermatologica. 2009;157:238-244. doi: 10.1159/000250839. DOI: https://doi.org/10.1159/000250839
Baek JO, Byamba D, Wu WH, Kim TG and Lee MG. Assessment of an imiquimod-induced psoriatic mouse model in relation to oxidative stress. Arch Dermatol Res. 2012;304:699-706. doi: 10.1007/s00403-012-1272-y. DOI: https://doi.org/10.1007/s00403-012-1272-y
Gulcan E, Kuçuk A, Çayci K, Tosun M, Emre H, Koral L, et al. Topical effects of nebivolol on wounds in diabetic rats. Eur J Pharm Sci. 2012;47(2):451-455. doi: 10.1016/j.ejps.2012.06.017. DOI: https://doi.org/10.1016/j.ejps.2012.06.017
Underwood W, Anthony R. AVMA guidelines for the euthanasia of animals: 2020 edition. Retrieved on March 2020; 2013: 2020-2021.
Cardiff RD, Miller CH, Munn RJ. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc. 2014;2014(6):655-658. doi: 10.1101/pdb.prot073411. DOI: https://doi.org/10.1101/pdb.prot073411
Kang D, Li B, Luo L, Jiang W, Lu Q, Rong M, et al. Curcumin shows excellent therapeutic effect on psoriasis in mouse model. Biochimie. 2016;123:73-80. doi: 10.1016/j.biochi.2016.01.013. DOI: https://doi.org/10.1016/j.biochi.2016.01.013
Mohammed SS, Kadhim HM, AL-Sudani IM and Musatafa WW. Anti-inflammatory effects of topically applied azilsartan in a mouse model of imiquimod-induced psoriasis. Int J Drug Del Technol. 2022;12:1250-1255. DOI: https://doi.org/10.25258/ijddt.12.3.53
Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Method. 2007;39:175-191. doi: 10.3758/bf03193146. DOI: https://doi.org/10.3758/BF03193146
Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4:303-306. doi: 10.4103/0976-500x.119726. DOI: https://doi.org/10.4103/0976-500X.119726
Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199-204. doi: 10.1111/j.1365-2125.1994.tb04342.x. DOI: https://doi.org/10.1111/j.1365-2125.1994.tb04342.x
Ilhan A, Yilmaz HR, Armutcu F, Gurel A, Akyol O. The protective effect of nebivolol on ischemia/reperfusion injury in rabbit spinal cord. Prog Neuropsychopharmacol Biol Psychiatr. 2004;28:1153-1160. doi: 10.1016/j.pnpbp.2004.06.023. DOI: https://doi.org/10.1016/j.pnpbp.2004.06.023
Kumar R, Mal K, Begum J, Shaukat F. Comparison of nebivolol and bisoprolol for cardiovascular mortality in hypertensive patients. Cureus. 2019;11:e6453. doi: 10.7759/cureus.6453. DOI: https://doi.org/10.7759/cureus.6453
Alba BK, Greaney JL, Ferguson SB, Alexander LM. Endothelial function is impaired in the cutaneous microcirculation of adults with psoriasis through reductions in nitric oxide-dependent vasodilation. Am J Physiol Heart Circ Physiol. 2018;314:H343-h349. doi: 10.1152/ajpheart.00446.2017. DOI: https://doi.org/10.1152/ajpheart.00446.2017
Zainal IG. Study the profile of some antioxidant markers in diabetic mellitus and non-diabetic patients with cardiovascular disease. Med J Babylon. 2022;19:653-658. DOI: https://doi.org/10.4103/MJBL.MJBL_190_22
Nemati H, Khodarahmi R, Sadeghi M, Ebrahimi A, Rezaei M, Vaisi-Raygani A. Antioxidant status in patients with psoriasis. Cell Biochem Funct. 2014;32:268-273. doi: 10.1002/cbf.3011. DOI: https://doi.org/10.1002/cbf.3011
Barygina VV, Becatti M, Soldi G, Prignano F, Lotti T, Nassi P, et al. Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy. Redox Rep. 2013;18(3):100-106. doi: 10.1179/1351000213Y.0000000045. DOI: https://doi.org/10.1179/1351000213Y.0000000045
Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - A 30th anniversary update. Acta Physiol (Oxf). 2017;219:22-96. doi: 10.1111/apha.12646. DOI: https://doi.org/10.1111/apha.12646
Vanhoutte PM, Zhao Y, Xu A, Leung SW. Thirty years of saying NO: Sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator. Circ Res. 2016;119:375-396. doi: 10.1161/circresaha.116.306531. DOI: https://doi.org/10.1161/CIRCRESAHA.116.306531
Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frölich JC. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol. 2000;50:377-379. doi: 10.1046/j.1365-2125.2000.00258.x. DOI: https://doi.org/10.1046/j.1365-2125.2000.00258.x
Celik T, Yuksel UC, Iyisoy A, Kursaklioglu H, Ozcan O, Kilic S, et al. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol. Int J Cardiol. 2007;116(2):206-211. doi: 10.1016/j.ijcard.2006.03.046. DOI: https://doi.org/10.1016/j.ijcard.2006.03.046
Wolf SC, Sauter G, Preyer M, Poerner T, Kempf VA, Risler T, et al. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem. 2007;19(1-4):129-136. doi: 10.1159/000099201. DOI: https://doi.org/10.1159/000099201
de Groot AA, Mathy MJ, van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol. 2004;43:148-153. doi: 10.1097/00005344-200401000-00022. DOI: https://doi.org/10.1097/00005344-200401000-00022
Michalak-Stoma A, Bartosińska J, Kowal M, Raczkiewicz D, Krasowska D, Chodorowska G. IL-17A in the psoriatic patients' serum and plaque scales as potential marker of the diseases severity and obesity. Mediators Inflamm. 2020;2020:7420823. doi: 10.1155/2020/7420823. DOI: https://doi.org/10.1155/2020/7420823
Horváth S, Komlódi R, Perkecz A, Pintér E, Gyulai R, Kemény Á. Methodological refinement of Aldara-induced psoriasiform dermatitis model in mice. Sci Rep. 2019;9:3685. doi: 10.1038/s41598-019-39903-x. DOI: https://doi.org/10.1038/s41598-019-39903-x
Lin YK, Yang SH, Chen CC, Kao HC, Fang JY. Using imiquimod-induced psoriasis-like skin as a model to measure the skin penetration of anti-psoriatic drugs. PLoS One. 2015;10:e0137890. doi: 10.1371/journal.pone.0137890. DOI: https://doi.org/10.1371/journal.pone.0137890
Rodríguez-Martínez S, Cancino-Diaz JC, Martínez‐Torrez I, Pérez-Tapia SM, Cancino-Diaz ME. Psoriatic animal models developed for the study of the disease. In: An Interdisciplinary Approach to Psoriasis, Chiriac A, (Ed.), 2017. doi: 10.5772/intechopen.68305. DOI: https://doi.org/10.5772/intechopen.68305
Wasilewska A, Winiarska M, Olszewska M, Rudnicka L. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol. 2016;33:247-252. doi: 10.5114/ada.2016.61599. DOI: https://doi.org/10.5114/ada.2016.61599
Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev. 2015;14:286-292. doi: 10.1016/j.autrev.2014.11.012. DOI: https://doi.org/10.1016/j.autrev.2014.11.012
Nguyen H, Chiasson VL, Chatterjee P, Kopriva SE, Young KJ, Mitchell BM. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res. 2013;97:696-704. doi: 10.1093/cvr/cvs422. DOI: https://doi.org/10.1093/cvr/cvs422
Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160:319-324. doi: 10.1111/j.1365-2133.2008.08902.x. DOI: https://doi.org/10.1111/j.1365-2133.2008.08902.x
Cordiali-Fei P, Bianchi L, Bonifati C, Trento E, Ruzzetti M, Francesconi F, et al. Immunologic biomarkers for clinical and therapeutic management of psoriasis. Mediators Inflamm. 2014;2014:236060. doi: 10.1155/2014/236060. DOI: https://doi.org/10.1155/2014/236060
Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534-542. doi: 10.1016/j.jaad.2004.02.021. DOI: https://doi.org/10.1016/j.jaad.2004.02.021
Abanmi A, Al Harthi F, Al Agla R, Khan HA, Tariq M. Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int J Dermatol. 2005;44:82-83. doi: 10.1111/j.1365-4632.2004.02082.x. DOI: https://doi.org/10.1111/j.1365-4632.2004.02082.x
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370:263-271. doi: 10.1016/s0140-6736(07)61128-3. DOI: https://doi.org/10.1016/S0140-6736(07)61128-3
Marina ME, Roman, II, Constantin AM, Mihu CM, Tătaru AD. VEGF involvement in psoriasis. Clujul Med. 2015;88:247-252. doi: 10.15386/cjmed-494. DOI: https://doi.org/10.15386/cjmed-494
Boehncke WH, Boehncke S. Managing comorbidities in psoriasis. Actas Dermosifiliogr. 2009;100(Suppl 2):22-27. doi: 10.1016/s0001-7310(09)73374-5. DOI: https://doi.org/10.1016/S0001-7310(09)73374-5
Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8:235-245. doi: 10.4103/2229-5178.209622. DOI: https://doi.org/10.4103/2229-5178.209622
Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi: 10.1155/2012/561018. DOI: https://doi.org/10.1155/2012/561018
Oakley RH, Ren R, Cruz-Topete D, Bird GS, Myers PH, Boyle MC, et al. Essential role of stress hormone signaling in cardiomyocytes for the prevention of heart disease. Proc Natl Acad Sci U S A. 2013;110(42):17035-17040. doi: 10.1073/pnas.1302546110. DOI: https://doi.org/10.1073/pnas.1302546110
Mori H, Arita K, Yamaguchi T, Hirai M, Kurebayashi Y. Effects of topical application of betamethasone on imiquimod-induced psoriasis-like skin inflammation in mice. Kobe J Med Sci. 2016; 62: E79-e88. PMID: 28239073.
التنزيلات
منشور
كيفية الاقتباس
إصدار
القسم
الرخصة
الحقوق الفكرية (c) 2024 Al-Rafidain Journal of Medical Sciences
هذا العمل مرخص بموجب Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).
